Compare Novartis AG (NVS) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Novartis AG trades at $143.44 (market cap $268.57B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.49 (market cap $25.27B). The key difference: Novartis AG is far larger — about 10.6× Royalty Pharma plc Class A Ordinary Shares's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| NVS | RPRX | |
|---|---|---|
Market Cap | $268.57B | $25.27B |
Volume | 1,532,573 | 3,671,183 |
Sector | Health | Health |
52-Week High | $168.62 | $63.96 |
52-Week Low | $121.80 | $35.44 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $309.89B | $32.50B |
Dividend Yield | 3.31% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
